Past EventNMBio Luncheon Meeting
NMBio’s 2019 kickoff meeting will feature two firms on the verge of breakout success as well as an overview on groundbreaking bioscience research that’s taking place at New Mexico Tech.
VisionQuest has developed and successfully deployed a software product for automatic analysis of retinal images in the detection of lesions in patients with diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma. Its automatic, real-time image quality screening system is also now being used in two commercial retinal cameras to ensure the highest possible retinal image. Speaker: Simon Barriga, Ph.D., CEO
VisionQuest receives a $3M Award to Use Artificial Intelligence to Save Lives of African Children Affected with Malaria
VisionQuest Uses Artificial Intelligence to Prevent Blindness in 12,500 people
Agilvax is a private company that discovers and develops immunotherapies to combat cancer and targeted vaccines against infectious diseases. Its lead asset is AX09 immunotherapy candidate for the treatment of aggressive forms of breast cancer. Immunization with AX09 elicits antibodies targeting breast cancer stem cells, a key cellular reservoir for relapse, metastatic progression and therapeutic resistance.
Agilvax is now a resident company at Johnson & Johnson Innovation, JLABS at the renowned Texas Medical Center—the world’s largest cancer center—located in Houston, TX. Read More »
Agilvax received a Fast Track Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). The grant will provide up to $2.3 million in funding for preclinical studies, cGMP manufacturing and a nonclinical toxicology study that will enable an investigational new drug application for Agilvax’s lead immunotherapy product, AX09. Read More »
Speaker: Michael Perrine, MS, MBA, Director of Business Development
NM Tech — Snezna Rogeli, Ph.D, Professor and Chair of the Biology Department will provide an overview of the three major branches of her group’s entrepreneurially-focused endeavors: a universal topical treatment for drug-resistant (and sensitive) bacterial and fungal infections, the anti-cancer drug AKS7 that also works against intracellular parasites trypanosoma and leishmania, and anti-gram-negative drugs for systemic application.
Date: January 24
Place: Lobo Rainforest Building
101 Broadway Blvd NE, Albuquerque, NM 87102 (add map location)
Fee: $20 for NMBio & NMTC members; $35 for non-members